Anthony M Casapao1, David M Jacobs2, Dana R Bowers3, Nicholas D Beyda4, Thomas J Dilworth5. 1. Husson University School of Pharmacy, Bangor, Maine. 2. University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York. 3. Kingman Regional Medical Center, Kingman, Arizona. 4. University of Houston College of Pharmacy, Houston, Texas. 5. Department of Pharmacy, Wheaton Franciscan Healthcare - St. Francis Hospital, Milwaukee, Wisconsin.
Abstract
STUDY OBJECTIVE: To determine whether early administration of adjuvant β-lactam in combination with vancomycin (COMBO) affects clinical outcomes compared to standard vancomycin therapy alone (STAN) among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection. DESIGN: Retrospective, multicenter cohort study. SETTING: Five academic or community hospitals throughout the United States. PATIENTS: Adults with MRSA bloodstream infections treated with vancomycin (≥ 72 hrs) with or without an intravenous β-lactam (≥ 48 hrs) initiated within 24 hours of initiating vancomycin. MEASUREMENTS AND MAIN RESULTS: The primary outcome was clinical failure, a composite endpoint including 30-day mortality, persistent bacteremia (≥ 7 days), bacteremia relapse, or change in antibiotic therapy during treatment due to clinical worsening. A multivariable logistic regression examined the impact of patient-, treatment-, and pathogen-level characteristics on clinical failure. A total of 201 patients were evaluated of whom 97 (48.3%) met the criteria for study inclusion; 40 (41.2%) in STAN and 57 (58.8%) in COMBO groups. Among patients in the STAN and COMBO groups, 30% and 24.6% experienced clinical failure, respectively (p=0.552). The median (interquartile range) duration of bacteremia in the STAN and COMBO groups was 4 days (2.5-6.5) and 3 days (2-5), respectively (p=0.048). In a multivariable analysis, receipt of COMBO therapy was inversely associated with clinical failure (adjusted odds ratio [aOR] 0.237, 95% confidence interval [CI] [0.057-0.982]; p=0.047). Other independent predictors of clinical failure included complicated bacteremia (aOR 6.856, 95% CI [1.641-28.649]; p=0.008) and antibiotic therapy not continued at discharge (aOR 45.404, 95% CI [9.383-219.714]; p<0.001). CONCLUSIONS: Receipt of COMBO therapy did not decrease the rate of clinical failure but was associated with expedited bacteremia clearance. Early adjuvant β-lactam therapy deserves continued evaluation and clinical consideration.
STUDY OBJECTIVE: To determine whether early administration of adjuvant β-lactam in combination with vancomycin (COMBO) affects clinical outcomes compared to standard vancomycin therapy alone (STAN) among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection. DESIGN: Retrospective, multicenter cohort study. SETTING: Five academic or community hospitals throughout the United States. PATIENTS: Adults with MRSA bloodstream infections treated with vancomycin (≥ 72 hrs) with or without an intravenous β-lactam (≥ 48 hrs) initiated within 24 hours of initiating vancomycin. MEASUREMENTS AND MAIN RESULTS: The primary outcome was clinical failure, a composite endpoint including 30-day mortality, persistent bacteremia (≥ 7 days), bacteremia relapse, or change in antibiotic therapy during treatment due to clinical worsening. A multivariable logistic regression examined the impact of patient-, treatment-, and pathogen-level characteristics on clinical failure. A total of 201 patients were evaluated of whom 97 (48.3%) met the criteria for study inclusion; 40 (41.2%) in STAN and 57 (58.8%) in COMBO groups. Among patients in the STAN and COMBO groups, 30% and 24.6% experienced clinical failure, respectively (p=0.552). The median (interquartile range) duration of bacteremia in the STAN and COMBO groups was 4 days (2.5-6.5) and 3 days (2-5), respectively (p=0.048). In a multivariable analysis, receipt of COMBO therapy was inversely associated with clinical failure (adjusted odds ratio [aOR] 0.237, 95% confidence interval [CI] [0.057-0.982]; p=0.047). Other independent predictors of clinical failure included complicated bacteremia (aOR 6.856, 95% CI [1.641-28.649]; p=0.008) and antibiotic therapy not continued at discharge (aOR 45.404, 95% CI [9.383-219.714]; p<0.001). CONCLUSIONS: Receipt of COMBO therapy did not decrease the rate of clinical failure but was associated with expedited bacteremia clearance. Early adjuvant β-lactam therapy deserves continued evaluation and clinical consideration.
Authors: Arnold S Bayer; Selvi C Ersoy; Warren E Rose; Ana M Bienvenida; Yan Q Xiong; Henry F Chambers Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191
Authors: T D Trinh; S C J Jorgensen; E J Zasowski; K C Claeys; A M Lagnf; S J Estrada; D J Delaportes; V Huang; K P Klinker; K S Kaye; S L Davis; M J Rybak Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Kyle C Molina; Taylor Morrisette; Matthew A Miller; Vanthida Huang; Douglas N Fish Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Melicent Peck; Michael E Rothenberg; Rong Deng; Nicholas Lewin-Koh; Gaohong She; Amrita V Kamath; Montserrat Carrasco-Triguero; Ola Saad; Aide Castro; Lisa Teufel; Daniel S Dickerson; Marisa Leonardelli; Jorge A Tavel Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Alessander O Guimaraes; Yi Cao; Kyu Hong; Oleg Mayba; Melicent C Peck; Johnny Gutierrez; Felicia Ruffin; Montserrat Carrasco-Triguero; Jason B Dinoso; Angelo Clemenzi-Allen; Catherine A Koss; Stacey A Maskarinec; Henry F Chambers; Vance G Fowler; Amos Baruch; Carrie M Rosenberger Journal: Clin Infect Dis Date: 2019-04-24 Impact factor: 9.079
Authors: Evan J Zasowski; Trang D Trinh; Safana M Atwan; Marina Merzlyakova; Abdalhamid M Langf; Sahil Bhatia; Michael J Rybak Journal: Open Forum Infect Dis Date: 2019-04-03 Impact factor: 3.835
Authors: Sara Alosaimy; Noor L Sabagha; Abdalhamid M Lagnf; Evan J Zasowski; Taylor Morrisette; Sarah C J Jorgensen; Trang D Trinh; Ryan P Mynatt; Michael J Rybak Journal: Infect Dis Ther Date: 2020-04-04